Document is current

Article History

Received: 1 May 2024

Accepted: 15 July 2024

First Online: 1 August 2024

Declarations

:

: Nancy M Holekamp reports employment by F. Hoffmann-La Roche Ltd. (visiting professor); consulting fees from Apellis, Bayer, Biogen, Boehringer Ingelheim, Cardinal, Clearside, EyePoint, Genentech, Inc., Gyroscope, Medpace, Medscape, Notal Vision, Novartis, Regeneron, Roche, Stealth, and Vial; speaker’s bureaus for Apellis, Bausch + Lomb, Genentech, Inc., and Regeneron; contracted research for Gemini, Genentech, Inc., Gyroscope, and Notal Vision; data monitoring and safety committees for Editas, Ocuphire, and Roche; and stock or stock options in Apellis, Nacuity, and Notal Vision. Manejeh Yaqub reports employment by Genentech, Inc.; stock/stock options in F. Hoffmann-La Roche Ltd.; and non-financial involvement with the Kashmiri Group of North America. Shrirang V Ranade and Ronald A Cantrell report employment by Genentech, Inc.; and stock/stock options in F. Hoffmann-La Roche Ltd. Sheena Singh reports employment by Envision Pharma Group, which was contracted by Genentech, Inc./Roche (sponsor) for conducting and managing the systematic literature reviews on behalf of the sponsor. Gus Gazzard reports personal fees from Alcon, Allergan, Belkin, Equinox, Genentech, Inc./Roche, Glaukos, iStar, Ivantis, Lumibird, Reichert, Sight Sciences, Thea, Vialase, Visufarma, and Zeiss; grants from Belkin and Santen, Thea; and non-financial involvement with the patient advocacy group, GlaucomaUK, outside the submitted work.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.